ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©Åú×¼ÂØ¿¨Ä¹£¨Ó¢ÎÄÉÌÆ·Ãû£ºLEQEMBI?ÖÐÎÄÉÌÆ·Ãû£ºÀÖÒâ±£?£©¾²Âö×¢É䣨IV£©Î¬³Ö¼ÁÁ¿ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡

  • ÿËÄÖÜÒ»´ÎµÄά³Ö¼ÁÁ¿ÖÎÁÆ¿ÉÄܸü±ãÓÚ»¼ÕߺÍÕÕ»¤Õß¼ÌÐø°¢¶û´Äº£Ä¬²¡µÄÖÎÁÆ £»
  • °ß¿éÇå³ýºó£¬°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹²¢²»»áÍ£Ö¹ £»
  • Á¬ÐøʹÓÃLEQEMBIÖÎÁÆ¿ÉÒÔ¼õ»º¼²²¡½øÕ¹£¬²¢ÑÓ³¤ÖÎÁÆЧÒæ¡£

 

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼£¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ÒÑÅú×¼ÂØ¿¨Ä¹£¨ÃÀ¹úÉÌÆ·Ãû£ºLEQEMBI?£¬ÖÐÎÄÉÌÆ·Ãû£ºÀÖÒâ±£?£©Ã¿ËÄÖÜÒ»´ÎµÄ¾²Âö×¢É䣨IV£©Î¬³Ö¼ÁÁ¿¸øÒ©µÄÔö²¹ÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루sBLA£©¡£ÂØ¿¨Ä¹ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆΪÔçÆÚAD£©¡£ÔÚÍê³É18¸öÔ¡¢Ã¿Á½ÖÜÒ»´ÎµÄÆðʼ½×¶ÎÖÎÁƺ󣬿ɿ¼ÂÇת»»ÎªÃ¿ËÄÖÜÒ»´Î¡¢10 mg/kgµÄά³Ö¼ÁÁ¿¸øÒ©·½°¸£¬»ò¼ÌÐøÿÁ½ÖÜÒ»´Î¡¢10 mg/kgµÄ¸øÒ©·½°¸¡£

 

¸ÃÔö²¹ÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루sBLA£©»ùÓÚ¶ÔIIÆÚÑо¿£¨Ñо¿201£©¼°Æäºã¾ÃÀ©Õ¹£¨LTE£©Ñо¿£¬ÒÔ¼°Clarity ADÑо¿£¨Ñо¿301£©¼°ÆäLTEÑо¿µÄÊÓ²ìÊý¾Ý½øÐн¨Ä£·ÖÎö¡£Ä£ÐÍÄ£ÄâÔ¤²â£¬ÔÚÍê³É18¸öÔ¡¢Ã¿Á½ÖÜÒ»´ÎµÄÆðʼ½×¶ÎÖÎÁƺ󣬿ɿ¼ÂÇת»»ÎªÃ¿ËÄÖÜÒ»´Î¡¢10?mg/kgµÄά³Ö¼ÁÁ¿¸øÒ©·½°¸£¬»ò¼ÌÐøÿÁ½ÖÜÒ»´Î¡¢10?mg/kgµÄ¸øÒ©·½°¸£¬½«Äܹ»±£³ÖÖÎÁƵÄÁÙ´²ºÍÉúÎï±êÖ¾Îï·½ÃæµÄÒæ´¦¡£°¢¶û´Äº£Ä¬²¡£¨AD£©ÊÇÒ»¸öÁ¬Ðø½øÐеÄÉñ¾­¶¾ÐÔ¹ý³Ì£¬Ê¼ÓÚ°ß¿é³Á»ý֮ǰ£¬²¢ÔÚÆäºó¼ÌÐøÉú³¤1,2,3¡£ÂØ¿¨Ä¹Í¨¹ýÁ¬ÐøÇå³ýÔ­ÏËάºÍ¿ìËÙÇå³ý°ß¿é·´¿¹AD¡£Í¨¹ýÁ¬Ðø¸øÒ©£¬ÂØ¿¨Ä¹¿ÉÇå³ý¸ß¶¾ÐÔÔ­ÏËά£¬¼´Ê¹A¦Â°ß¿éÒÑ´Ó´óÄÔÖÐÇå³ý£¬Ô­ÏËάÈÔ»á¼ÌÐø¶ÔÉñ¾­ÔªÔì³ÉËðÉË¡£

 

ÂØ¿¨Ä¹ÒÑÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Öйú¡¢º«¹ú¡¢ÖйúÏã¸Û¡¢ÒÔÉ«ÁС¢°¢ÁªÇõ¡¢Ó¢¹ú¡¢Ä«Î÷¸çºÍÖйú°ÄÃŵȹú¼ÒºÍµØÓò»ñµÃÅú×¼¡£2024Äê11Ô£¬Å·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©ÏÂÊôµÄÈËÓÃҩƷίԱ»á£¨CHMP£©¶Ô¸ÃÖÎÁÆÒ©Îï¸øÓèÁË»ý¼«Òâ¼û£¬½¨ÒéÓèÒÔÅú×¼¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÔÚ17¸ö¹ú¼ÒºÍµØÓòÌá½»ÁËÂØ¿¨Ä¹µÄÉÏÊÐÉêÇë¡£´ËÍ⣬2025Äê1Ô£¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ÒÑÊÜÀíÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ìá½»µÄÂØ¿¨Ä¹Æ¤ÏÂ×Ô¶¯×¢ÉäÿÖÜά³Ö¼ÁÁ¿¸øÒ©µÄÔö²¹ÉúÎïÖÆÆ·Ðí¿É£¨BLA£©ÉêÇ룬²¢½«¡¶´¦·½Ò©Óû§Óöȷ¨°¸¡·£¨PDUFA£©Ðж¯ÈÕÆÚ¶¨Îª2025Äê8ÔÂ31ÈÕ¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

ýÌåÁªÏµ

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120

 

Eisai Inc. (U.S.)

Julie Edelman

1-862-213-5915

Julie_Edelman@eisai.com

 

Eisai Europe, Ltd.

EMEA Communications Department

+44 (0) 786 601 1272

Emea-comms@eisai.net

 

Biogen Inc.

Jack Cox

+ 1-781-464-3260

public.affairs@biogen.com

 

Ͷ×ÊÕßÁªÏµ

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

 

Biogen Inc.

Tim Power

+1-781-464-2442

IR@biogen.com

 

 

²Î¿¼×ÊÁÏ£º

  1. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc.
  2. Iwatsubo T, Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, Cohen S. Clarity AD: a phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer¡¯s disease. Presented at: CTAD Conference; November 29-December 2, 2022; San Francisco, CA.
  3. Hampel H, Hardy J, Blennow K, et al. The amyloid-¦Â pathway in Alzheimer¡¯s disease. Mol Psychiatry. 2021;26(10):5481-5503.

 

±àºÅ£ºECN-2025-0012